Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer
The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we...
Gespeichert in:
| Veröffentlicht in: | International journal of cancer 2025-01, Vol.156 (2), p.456-466 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 466 |
|---|---|
| container_issue | 2 |
| container_start_page | 456 |
| container_title | International journal of cancer |
| container_volume | 156 |
| creator | van de Weerd, Simone Torang, Arezo van den Berg, Inge Lammers, Veerle van den Bergh, Saskia Brouwer, Nelleke Nagtegaal, Iris D Koopman, Miriam Vink, Geraldine R van der Baan, Frederieke H van Krieken, Han Koster, Jan Ijzermans, Jan N Roodhart, Jeanine M L Medema, Jan Paul |
| description | The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p |
| doi_str_mv | 10.1002/ijc.35120 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11578081</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3090637432</sourcerecordid><originalsourceid>FETCH-LOGICAL-c294t-c46e85e47943a5198d5e511360ba7f2aed96c6dbc8338d34aeb2b011c99b0d9e3</originalsourceid><addsrcrecordid>eNpdkU1v1DAQhi0EotvCgT-ALHGhh5RxJl8-oVLxsVIlLnC2HGfSzSqxg51E2n_PQEsFnGxpHj2ad14hXim4UgD5u-HorrBUOTwROwW6ziBX5VOx4xlktcLqTJyndARQqoTiuThDzT_EfCe2D-SpHxYZemm747pZv0h3oCksB4p2PsngZSS3xkjekewjkUxr3IbNjnKmKF3wiXxak5zCyOBoIwPtcppJDl6mxd6R3O_3DI7scpY18YV41tsx0cuH90J8__Tx282X7Pbr5_3N9W3mcl0smSsqakoqal2gLZVuupJKxYGgtXWfW-p05aqudQ1i02Fhqc1bTum0bqHThBfi_b13XtuJOkd-iXY0cxwmG08m2MH8O_HDwdyFzfB96gYaxYa3D4YYfqyUFjMNydE4Wk9hTQZBQ4V1gTmjb_5Dj2GNnvMZVMgUAhZMXd5TLoaUIvWP2ygwv-o0XKf5XSezr_9e_5H80x_-BK47nQM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3130633034</pqid></control><display><type>article</type><title>Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><creator>van de Weerd, Simone ; Torang, Arezo ; van den Berg, Inge ; Lammers, Veerle ; van den Bergh, Saskia ; Brouwer, Nelleke ; Nagtegaal, Iris D ; Koopman, Miriam ; Vink, Geraldine R ; van der Baan, Frederieke H ; van Krieken, Han ; Koster, Jan ; Ijzermans, Jan N ; Roodhart, Jeanine M L ; Medema, Jan Paul</creator><creatorcontrib>van de Weerd, Simone ; Torang, Arezo ; van den Berg, Inge ; Lammers, Veerle ; van den Bergh, Saskia ; Brouwer, Nelleke ; Nagtegaal, Iris D ; Koopman, Miriam ; Vink, Geraldine R ; van der Baan, Frederieke H ; van Krieken, Han ; Koster, Jan ; Ijzermans, Jan N ; Roodhart, Jeanine M L ; Medema, Jan Paul</creatorcontrib><description>The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p < .01, HR 0.19; p < .01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p = .51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.</description><identifier>ISSN: 0020-7136</identifier><identifier>ISSN: 1097-0215</identifier><identifier>EISSN: 1097-0215</identifier><identifier>DOI: 10.1002/ijc.35120</identifier><identifier>PMID: 39115332</identifier><language>eng</language><publisher>United States: Wiley Subscription Services, Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biomarkers, Tumor - genetics ; Chemotherapy ; Chemotherapy, Adjuvant - methods ; Cohort analysis ; Colon cancer ; Colonic Neoplasms - classification ; Colonic Neoplasms - drug therapy ; Colonic Neoplasms - genetics ; Colonic Neoplasms - mortality ; Colonic Neoplasms - pathology ; Colorectal cancer ; Disease-Free Survival ; Female ; Humans ; Male ; Medical prognosis ; Middle Aged ; Multivariate analysis ; Neoplasm Recurrence, Local - drug therapy ; Neoplasm Recurrence, Local - pathology ; Neoplasm Staging ; Patients ; Prognosis ; RESEARCH ARTICLE ; Survival ; Tumors</subject><ispartof>International journal of cancer, 2025-01, Vol.156 (2), p.456-466</ispartof><rights>2024 The Author(s). International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.</rights><rights>2024. This article is published under http://creativecommons.org/licenses/by-nc-nd/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2024 The Author(s). published by John Wiley & Sons Ltd on behalf of UICC.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c294t-c46e85e47943a5198d5e511360ba7f2aed96c6dbc8338d34aeb2b011c99b0d9e3</cites><orcidid>0000-0002-2268-9668 ; 0000-0002-7912-3964 ; 0000-0002-7529-4686 ; 0000-0003-1398-8970</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39115332$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>van de Weerd, Simone</creatorcontrib><creatorcontrib>Torang, Arezo</creatorcontrib><creatorcontrib>van den Berg, Inge</creatorcontrib><creatorcontrib>Lammers, Veerle</creatorcontrib><creatorcontrib>van den Bergh, Saskia</creatorcontrib><creatorcontrib>Brouwer, Nelleke</creatorcontrib><creatorcontrib>Nagtegaal, Iris D</creatorcontrib><creatorcontrib>Koopman, Miriam</creatorcontrib><creatorcontrib>Vink, Geraldine R</creatorcontrib><creatorcontrib>van der Baan, Frederieke H</creatorcontrib><creatorcontrib>van Krieken, Han</creatorcontrib><creatorcontrib>Koster, Jan</creatorcontrib><creatorcontrib>Ijzermans, Jan N</creatorcontrib><creatorcontrib>Roodhart, Jeanine M L</creatorcontrib><creatorcontrib>Medema, Jan Paul</creatorcontrib><title>Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer</title><title>International journal of cancer</title><addtitle>Int J Cancer</addtitle><description>The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p < .01, HR 0.19; p < .01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p = .51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Chemotherapy</subject><subject>Chemotherapy, Adjuvant - methods</subject><subject>Cohort analysis</subject><subject>Colon cancer</subject><subject>Colonic Neoplasms - classification</subject><subject>Colonic Neoplasms - drug therapy</subject><subject>Colonic Neoplasms - genetics</subject><subject>Colonic Neoplasms - mortality</subject><subject>Colonic Neoplasms - pathology</subject><subject>Colorectal cancer</subject><subject>Disease-Free Survival</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Multivariate analysis</subject><subject>Neoplasm Recurrence, Local - drug therapy</subject><subject>Neoplasm Recurrence, Local - pathology</subject><subject>Neoplasm Staging</subject><subject>Patients</subject><subject>Prognosis</subject><subject>RESEARCH ARTICLE</subject><subject>Survival</subject><subject>Tumors</subject><issn>0020-7136</issn><issn>1097-0215</issn><issn>1097-0215</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2025</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpdkU1v1DAQhi0EotvCgT-ALHGhh5RxJl8-oVLxsVIlLnC2HGfSzSqxg51E2n_PQEsFnGxpHj2ad14hXim4UgD5u-HorrBUOTwROwW6ziBX5VOx4xlktcLqTJyndARQqoTiuThDzT_EfCe2D-SpHxYZemm747pZv0h3oCksB4p2PsngZSS3xkjekewjkUxr3IbNjnKmKF3wiXxak5zCyOBoIwPtcppJDl6mxd6R3O_3DI7scpY18YV41tsx0cuH90J8__Tx282X7Pbr5_3N9W3mcl0smSsqakoqal2gLZVuupJKxYGgtXWfW-p05aqudQ1i02Fhqc1bTum0bqHThBfi_b13XtuJOkd-iXY0cxwmG08m2MH8O_HDwdyFzfB96gYaxYa3D4YYfqyUFjMNydE4Wk9hTQZBQ4V1gTmjb_5Dj2GNnvMZVMgUAhZMXd5TLoaUIvWP2ygwv-o0XKf5XSezr_9e_5H80x_-BK47nQM</recordid><startdate>20250115</startdate><enddate>20250115</enddate><creator>van de Weerd, Simone</creator><creator>Torang, Arezo</creator><creator>van den Berg, Inge</creator><creator>Lammers, Veerle</creator><creator>van den Bergh, Saskia</creator><creator>Brouwer, Nelleke</creator><creator>Nagtegaal, Iris D</creator><creator>Koopman, Miriam</creator><creator>Vink, Geraldine R</creator><creator>van der Baan, Frederieke H</creator><creator>van Krieken, Han</creator><creator>Koster, Jan</creator><creator>Ijzermans, Jan N</creator><creator>Roodhart, Jeanine M L</creator><creator>Medema, Jan Paul</creator><general>Wiley Subscription Services, Inc</general><general>John Wiley & Sons, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>7TO</scope><scope>7U9</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2268-9668</orcidid><orcidid>https://orcid.org/0000-0002-7912-3964</orcidid><orcidid>https://orcid.org/0000-0002-7529-4686</orcidid><orcidid>https://orcid.org/0000-0003-1398-8970</orcidid></search><sort><creationdate>20250115</creationdate><title>Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer</title><author>van de Weerd, Simone ; Torang, Arezo ; van den Berg, Inge ; Lammers, Veerle ; van den Bergh, Saskia ; Brouwer, Nelleke ; Nagtegaal, Iris D ; Koopman, Miriam ; Vink, Geraldine R ; van der Baan, Frederieke H ; van Krieken, Han ; Koster, Jan ; Ijzermans, Jan N ; Roodhart, Jeanine M L ; Medema, Jan Paul</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c294t-c46e85e47943a5198d5e511360ba7f2aed96c6dbc8338d34aeb2b011c99b0d9e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2025</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Chemotherapy</topic><topic>Chemotherapy, Adjuvant - methods</topic><topic>Cohort analysis</topic><topic>Colon cancer</topic><topic>Colonic Neoplasms - classification</topic><topic>Colonic Neoplasms - drug therapy</topic><topic>Colonic Neoplasms - genetics</topic><topic>Colonic Neoplasms - mortality</topic><topic>Colonic Neoplasms - pathology</topic><topic>Colorectal cancer</topic><topic>Disease-Free Survival</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Multivariate analysis</topic><topic>Neoplasm Recurrence, Local - drug therapy</topic><topic>Neoplasm Recurrence, Local - pathology</topic><topic>Neoplasm Staging</topic><topic>Patients</topic><topic>Prognosis</topic><topic>RESEARCH ARTICLE</topic><topic>Survival</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>van de Weerd, Simone</creatorcontrib><creatorcontrib>Torang, Arezo</creatorcontrib><creatorcontrib>van den Berg, Inge</creatorcontrib><creatorcontrib>Lammers, Veerle</creatorcontrib><creatorcontrib>van den Bergh, Saskia</creatorcontrib><creatorcontrib>Brouwer, Nelleke</creatorcontrib><creatorcontrib>Nagtegaal, Iris D</creatorcontrib><creatorcontrib>Koopman, Miriam</creatorcontrib><creatorcontrib>Vink, Geraldine R</creatorcontrib><creatorcontrib>van der Baan, Frederieke H</creatorcontrib><creatorcontrib>van Krieken, Han</creatorcontrib><creatorcontrib>Koster, Jan</creatorcontrib><creatorcontrib>Ijzermans, Jan N</creatorcontrib><creatorcontrib>Roodhart, Jeanine M L</creatorcontrib><creatorcontrib>Medema, Jan Paul</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>van de Weerd, Simone</au><au>Torang, Arezo</au><au>van den Berg, Inge</au><au>Lammers, Veerle</au><au>van den Bergh, Saskia</au><au>Brouwer, Nelleke</au><au>Nagtegaal, Iris D</au><au>Koopman, Miriam</au><au>Vink, Geraldine R</au><au>van der Baan, Frederieke H</au><au>van Krieken, Han</au><au>Koster, Jan</au><au>Ijzermans, Jan N</au><au>Roodhart, Jeanine M L</au><au>Medema, Jan Paul</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer</atitle><jtitle>International journal of cancer</jtitle><addtitle>Int J Cancer</addtitle><date>2025-01-15</date><risdate>2025</risdate><volume>156</volume><issue>2</issue><spage>456</spage><epage>466</epage><pages>456-466</pages><issn>0020-7136</issn><issn>1097-0215</issn><eissn>1097-0215</eissn><abstract>The consensus molecular subtype (CMS) classification divides colon tumors into four subtypes holding promise as a predictive biomarker. However, the effect of adjuvant chemotherapy on recurrence free survival (RFS) per CMS in stage III patients remains inadequately explored. With this intention, we selected stage III colon cancer (CC) patients from the MATCH cohort (n = 575) and RadboudUMC (n = 276) diagnosed between 2005 and 2018. Patients treated with and without adjuvant chemotherapy were matched based on tumor location, T- and N-stage (n = 522). Tumor material was available for 464 patients, with successful RNA extraction and CMS subtyping achieved in 390 patients (surgery alone group: 192, adjuvant chemotherapy group: 198). In the overall cohort, CMS4 was associated with poorest prognosis (HR 1.55; p = .03). Multivariate analysis revealed favorable RFS for the adjuvant chemotherapy group in CMS1, CMS2, and CMS4 tumors (HR 0.19; p = .01, HR 0.27; p < .01, HR 0.19; p < .01, respectively), while no significant difference between treatment groups was observed within CMS3 (HR 0.68; p = .51). CMS subtyping in this non-randomized cohort identified patients with poor prognosis and patients who may not benefit significantly from adjuvant chemotherapy.</abstract><cop>United States</cop><pub>Wiley Subscription Services, Inc</pub><pmid>39115332</pmid><doi>10.1002/ijc.35120</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2268-9668</orcidid><orcidid>https://orcid.org/0000-0002-7912-3964</orcidid><orcidid>https://orcid.org/0000-0002-7529-4686</orcidid><orcidid>https://orcid.org/0000-0003-1398-8970</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0020-7136 |
| ispartof | International journal of cancer, 2025-01, Vol.156 (2), p.456-466 |
| issn | 0020-7136 1097-0215 1097-0215 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11578081 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete |
| subjects | Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biomarkers, Tumor - genetics Chemotherapy Chemotherapy, Adjuvant - methods Cohort analysis Colon cancer Colonic Neoplasms - classification Colonic Neoplasms - drug therapy Colonic Neoplasms - genetics Colonic Neoplasms - mortality Colonic Neoplasms - pathology Colorectal cancer Disease-Free Survival Female Humans Male Medical prognosis Middle Aged Multivariate analysis Neoplasm Recurrence, Local - drug therapy Neoplasm Recurrence, Local - pathology Neoplasm Staging Patients Prognosis RESEARCH ARTICLE Survival Tumors |
| title | Benefit of adjuvant chemotherapy on recurrence free survival per consensus molecular subtype in stage III colon cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-01T19%3A36%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Benefit%20of%20adjuvant%20chemotherapy%20on%20recurrence%20free%20survival%20per%20consensus%20molecular%20subtype%20in%20stage%20III%20colon%20cancer&rft.jtitle=International%20journal%20of%20cancer&rft.au=van%20de%20Weerd,%20Simone&rft.date=2025-01-15&rft.volume=156&rft.issue=2&rft.spage=456&rft.epage=466&rft.pages=456-466&rft.issn=0020-7136&rft.eissn=1097-0215&rft_id=info:doi/10.1002/ijc.35120&rft_dat=%3Cproquest_pubme%3E3090637432%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3130633034&rft_id=info:pmid/39115332&rfr_iscdi=true |